×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
LON:PEBI

Port Erin Biopharma Investments Share Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
4.50
4.50
52-Week Range
N/A
Volume
8,294 shs
Average Volume
43,123 shs
Market Capitalization
£1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Receive PEBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Port Erin Biopharma Investments and its competitors with MarketBeat's FREE daily newsletter.

PEBI Stock Forecast (MarketRank)

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

About Port Erin Biopharma Investments

Port Erin Biopharma Investments Limited is a principal investment firm specializing in investments in equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Port Erin Biopharma Investments Limited was founded on May 3, 2011 and is based in Isle of Man, United Kingdom.

PEBI Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£28.30 thousand
Book Value
GBX 8.10 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.04 million
Optionable
Not Optionable
Beta
N/A














Port Erin Biopharma Investments Frequently Asked Questions

Who are Port Erin Biopharma Investments' key executives?

Port Erin Biopharma Investments' management team includes the following people:
  • Mr. Denham Hervey Newall Eke, CFO, Fin. Director & Director (Age 67)

What is Port Erin Biopharma Investments' stock symbol?

Port Erin Biopharma Investments trades on the London Stock Exchange (LON) under the ticker symbol "PEBI."

How do I buy shares of Port Erin Biopharma Investments?

Shares of PEBI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

How much money does Port Erin Biopharma Investments make?

Port Erin Biopharma Investments (LON:PEBI) has a market capitalization of £0.00 and generates £28.30 thousand in revenue each year.

How can I contact Port Erin Biopharma Investments?

Port Erin Biopharma Investments' mailing address is 18 Athol Street, DOUGLAS, IM1 1JA, Isle of Man. The official website for Port Erin Biopharma Investments is www.porterinbiopharma.com. The company can be reached via phone at +44-1624-620711.

This page (LON:PEBI) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.